Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03931161
Other study ID # EVOCAR-1
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date September 4, 2019
Est. completion date May 6, 2024

Study information

Verified date October 2022
Source Imperial College Healthcare NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase IV, randomised, placebo-controlled, double-blind, parallel group study to determine the effect of Evolocumab treatment on carotid plaque morphology and composition in asymptomatic patients with >50% carotid artery stenosis.


Description:

In this study patients will be randomised in a 1:1 ratio to receive Evolocumab 140 mg every two weeks or matching placebo, to be administered for 12 months. After 12 months of treatment, patients will remain in follow-up for a further 12 months. High resolution magnetic resonance imaging (MRI) will be used to serially monitor the impact of Evolocumab on carotid plaque morphology and composition in patients with significant carotid stenosis who do not meet clinical criteria for carotid endarterectomy. This approach will reveal if clinically beneficial plaque regression occurs, without requiring the large patient cohorts or long follow-up needed for cardiovascular outcome trials. Results from this study will establish whether treatment with Evolocumab is likely to be beneficial to patients with asymptomatic carotid stenosis.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 33
Est. completion date May 6, 2024
Est. primary completion date May 6, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years - Sufficient English language ability to adequately understand the study - Able to give informed consent - Significant carotid artery plaque with 50-70% stenosis on ultrasound or MRI performed prior to screening - Significant asymptomatic carotid artery plaque with >70% stenosis on ultrasound or MRI performed prior to screening, but carotid endarterectomy or carotid artery stenting has been deemed unsuitable by multidisciplinary team during routine clinical care - Lipid-rich necrotic core (LRNC) on baseline MRI scan - Adequate image quality for MRI analysis. - LDL-C =2.6 mmol/L (100 mg/dL) - On stable dose of maximally-tolerated lipid-lowering therapy in accordance with UK national clinical guidelines (NICE CG18120) for =2 months prior to screening. Acceptable non-statin lipid-lowering medications include ezetimibe or a fibrate. Exclusion Criteria: - Any medical condition which, in the opinion of the investigators, would present an unacceptable risk to the participant if they were to take part in the trial, or prevent them from following the trial protocol - Current or previous treatment with a PCSK9 inhibitor - Eligible for PCSK9 inhibitor treatment under current NICE guidelines - Contra-indication to or inability to use Evolocumab treatment, including: - Sensitivity to Evolocumab or any associated excipients - Unable to tolerate or perform self-administration of Evolocumab by auto-injector - Lack of suitable refrigerated storage - Contra-indication to or inability to tolerate MRI - Estimated glomerular filtration rate (eGFR) =45 mL/min/1.73 m2 prior to MRI scan - Pregnancy or breast-feeding - Women of childbearing potential who are unwilling or unable to use a highly effective method of contraception

Study Design


Intervention

Drug:
Evolocumab Auto-Injector [Repatha]
Auto-Injector, 140 mg every two weeks.
Placebo Auto-Injector
Matching Placebo for the active comparator (Evolocumab)

Locations

Country Name City State
United Kingdom Imperial College Healthcare NHS Trust London

Sponsors (2)

Lead Sponsor Collaborator
Imperial College Healthcare NHS Trust Imperial College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory outcomes 1: Change in biochemical parameters - total cholesterol Absolute and percentage change compared to baseline in total cholesterol. 24 months
Other Exploratory outcomes 1: Change in biochemical parameters - LDL-C Absolute and percentage change compared to baseline in LDL-C. 24 months
Other Exploratory outcomes 1: Change in biochemical parameters - HDL-C Absolute and percentage change compared to baseline in high density lipoprotein-associated cholesterol (HDL-C). 24 months
Other Exploratory outcomes 1: Change in biochemical parameters - triglycerides Absolute and percentage change compared to baseline in triglycerides. 24 months
Other Exploratory outcomes 1: Change in biochemical parameters - lipoprotein (a) Absolute and percentage change compared to baseline in lipoprotein(a). 24 months
Other Exploratory outcomes 2: Number of patients with Cardio & cerebrovascular events - Ischaemic and non-ischaemic stroke Cardio- and cerebrovascular events [be adjudicated by the Investigators], including: Ischaemic and non-ischaemic stroke 24 months
Other Exploratory outcomes 2: Number of patients with Cardio & cerebrovascular events - TIA Cardio- and cerebrovascular events [be adjudicated by the Investigators], including: Transient ischaemic attack 24 months
Other Exploratory outcomes 2: Number of patients with Cardio & cerebrovascular events - Progression to carotid endarterectomy Cardio- and cerebrovascular events [be adjudicated by the Investigators], including: Progression to carotid endarterectomy 24 months
Other Exploratory outcomes 2: Number of patients with Cardio & cerebrovascular events - MI Cardio- and cerebrovascular events [be adjudicated by the Investigators], including: Myocardial infarction 24 months
Other Exploratory outcomes 2: Number of patients with Cardio & cerebrovascular events - Unstable angina Cardio- and cerebrovascular events [be adjudicated by the Investigators], including: Unstable angina 24 months
Other Exploratory outcomes 2: Number of patients with Cardio & cerebrovascular events - Hospitalisation for heart failure Cardio- and cerebrovascular events [be adjudicated by the Investigators], including: Hospitalisation for heart failure 24 months
Other Exploratory outcomes 2: Number of patients with Cardio & cerebrovascular events -PAD-related end points: peripheral revascularization, Cardio- and cerebrovascular events [be adjudicated by the Investigators], including: PAD-related end points: peripheral revascularization, 24 months
Primary Change in lipid-rich necrotic core Change in lipid-rich necrotic core (LRNC) size at 12 months, compared to baseline 12 months
Secondary Percentage of LRNC core Change in percentage lipid-rich necrotic core (LRNC) at 12 months, compared to baseline 12 months
Secondary LRNC regression Percentage of participants achieving LRNC regression at 12 months 12 months
Secondary LRNC volume Change in carotid plaque LRNC volume at other time-points, compared to baseline 24 months
Secondary LRNC percentage Change in carotid plaque LRNC percentage at other time-points, compared to baseline 24 months
Secondary Measures of other carotid plaque burden - Volume wall thickness Absolute and percentage change, compared to baseline, of volume wall thickness 24 months
Secondary Measures of other carotid plaque burden - Volume wall area Absolute and percentage change, compared to baseline, volume wall area 24 months
Secondary Measures of other carotid plaque burden - Calcification Absolute and percentage change, compared to baseline, of plaque composition (calcification) 24 months
Secondary Measures of other carotid plaque burden - Fibrous tissue volume Absolute and percentage change, compared to baseline, of plaque composition (fibrous tissue volume) 24 months
Secondary Measures of other carotid plaque burden - New intra-plaque haemorrhage Absolute and percentage change, compared to baseline, of plaque composition (new intra-plaque haemorrhage) 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT03353103 - Imaging of Unstable Carotid Plaque in Patient Referred to Endarterectomy Phase 2
Completed NCT03996148 - Time to Post-Anesthesia Neurological Evaluation With Three Different Anesthetic Techniques Phase 4
Recruiting NCT05968053 - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Completed NCT00318851 - Carotid Artery Stenting With Protection Registry Phase 3
Completed NCT00597974 - Neurological Outcome With Carotid Artery Stenting N/A
Active, not recruiting NCT05293067 - Troponin In Carotid Revascularization
Completed NCT03133429 - Clinical Study to Evaluate the Safety and Effectiveness of MER® Stents in Carotid Revascularisation. N/A
Recruiting NCT01440036 - The Correlation Between the Enzyme Paraoxigenase 1 (PON1) to Carotid Artery Atheromatous Plaque N/A
Completed NCT00417963 - ViVEXX Carotid Revascularization Trial (VIVA) Phase 3
Completed NCT00177346 - A Randomized Trial of Carotid Artery Stenting With and Without Cerebral Protection N/A
Recruiting NCT05574972 - Timing Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis(Timing Trial) N/A
Recruiting NCT02476396 - Structural Stability of Carotid Plaque and Symptomatology
Completed NCT05451485 - VFI in Healthy Vessels
Recruiting NCT06033963 - Safety and Efficacy of Remote Ischemic Conditioning in Patients With Carotid Artery Stenosis Receiving Carotid EndArterectomy N/A
Not yet recruiting NCT02224209 - Comparison of Staged Angioplasty and Routine Single-stage Stenting (CAS) in the Treatment of Carotid Artery Stenosis Phase 4
Completed NCT02006095 - Neuroimaging Correlates of Memory Decline Following Carotid Interventions
Terminated NCT01236508 - Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease Phase 4
Recruiting NCT05126238 - A Lithium-Based Medication to Improve Neurological Outcomes After Surgical Carotid Reconstruction Phase 3
Recruiting NCT06170580 - Improved Image Quality for Assessment of Carotid Artery Stenosis by Ultrafast Ultrasound FLOW Imaging
Recruiting NCT05800821 - Prediction of Cerebral Hyperperfusion Syndrome After Carotid Revascularization Using Deep Learning